You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 17, 2024

BAYER Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for BAYER
International Patents:1105
US Patents:54
Tradenames:109
Ingredients:73
NDAs:124
Patent Litigation for BAYER: See patent lawsuits for BAYER

Drugs and US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc OCUCLEAR oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 018471-001 May 30, 1986 DISCN No No ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes 8,637,553 ⤷  Sign Up Y Y ⤷  Sign Up
Bayer Pharms CORT-DOME hydrocortisone LOTION;TOPICAL 009895-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-001 Oct 8, 2013 AB RX Yes No 11,203,593 ⤷  Sign Up Y Y ⤷  Sign Up
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-004 Oct 8, 2013 AB RX Yes No 7,173,037 ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare MAGNEVIST gadopentetate dimeglumine INJECTABLE;INJECTION 019596-001 Jun 2, 1988 4,957,939 ⤷  Sign Up
Bayer Hlthcare MAGNEVIST gadopentetate dimeglumine INJECTABLE;INJECTION 021037-001 Mar 10, 2000 5,560,903 ⤷  Sign Up
Bayer Hlthcare ULTRAVIST (PHARMACY BULK) iopromide INJECTABLE;INJECTION 021425-001 Sep 20, 2002 4,364,921 ⤷  Sign Up
Bayer Healthcare Llc CLARITIN loratadine TABLET;ORAL 019658-002 Nov 27, 2002 4,659,716*PED ⤷  Sign Up
Bayer Hlthcare EOVIST gadoxetate disodium SOLUTION;INTRAVENOUS 022090-002 Feb 4, 2013 6,039,931 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAYER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12

Supplementary Protection Certificates for BAYER Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0402407 97C0005 Belgium ⤷  Sign Up PRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
2132206 15/2022 Austria ⤷  Sign Up PRODUCT NAME: FINERENON UND SALZE, SOLVATE UND SOLVATE DER SALZE DAVON; REGISTRATION NO/DATE: EU/1/21/1616 (MITTEILUNG) 20220217
2861072 2024C/512 Belgium ⤷  Sign Up PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
3106463 2020004 Norway ⤷  Sign Up PRODUCT NAME: LAROTREKTINIB OG/ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV, SAERLIG LAROTREKTINIBSULFAT INKLUDERT LAROTREKTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20191018
3106463 PA2020504,C3106463 Lithuania ⤷  Sign Up PRODUCT NAME: LAROTREKTINIBAS IR (ARBA) FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC LAROTREKTINIBO SULFATAS, ISKAITANT LAROTREKTINIBO VANDENILIO SULFATA; REGISTRATION NO/DATE: EU/1/19/1385 20190919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.